Predicting survival in gastric cancer: A prospective cohort study with 102 patients

Yıl 2019, Cilt: 3 Sayı: 5, 361 - 365, 28.05.2019

Koray Koşmaz , Mustafa Taner Bostancı Mehmet Ali Çaparlar Fatih Başak , Abdullah Şişik , Süleyman Kalcan Ali Ediz Kıvanç , Kemal Tekeşin , Gürhan Baş Orhan Alimoğlu

https://doi.org/10.28982/josam.560658

Cited By: 1

Öz

Aim: Gastric cancer is one of the most aggressive tumors of the gastrointestinal tract. Course of disease can be different in every case. The aim of this study was to evaluate prognosis of gastric cancer patients and factors affecting survival.
Methods: Observational cohort study was planned. Primary gastric cancer patients enrolled into study. Patients with rare tumors were excluded. Patients were divided in 4 groups; Group 1: patients suitable for surgery and underwent surgical resection, Group 2: patients that were discovered unresectable during operation, Group 3: patients that were radiological inoperable, Group 4: patients who refused the surgery. We analyzed survival among groups, and evaluated effecting factors.
Results: 102 patients were included in the study. Sixty-six patients underwent surgical resection (group 1). Five patients were diagnosed as inoperable during surgery (group 2). Six-teen patients were determined as inoperable by radiologic evaluation (group 3). Fifteen patients (group 4) were evaluated as operable; however they refused surgery. No differences were detected among groups in comparison of gender with p of 0.250 (table 1). However, age distribution was different between groups with p of 0.043 because group 4 is formed by older patients with mean age of 71.0 (10.0). Survival analysis showed that patients in group 1 (14.0 (5.1) months) had better survival than other groups (P=0.011). Male patients showed better survival than female patients (14 (1.9) vs 6 (1.8) months, P=0.002).
Conclusion: Although course of gastric cancer differs in every patient, proper surgery at certain stages seems to be a feasible treatment option with acceptable survival rates.

Anahtar Kelimeler

Gastric cancer, Survival, Course of disease

Mide kanserinde sağkalımı tahmin etmek: 102 hasta ile prospektif kohort çalışma

Öz

Amaç: Gastrik kanser, gastrointestinal sistemin en agresif tümörlerinden biridir. Her durumda hastalık seyri farklı olabilir. Bu çalışmanın amacı, mide kanseri hastalarının prognozunu ve sağkalımı etkileyen faktörleri değerlendirmektir.
Yöntemler: Gözlemsel kohort çalışması planlandı. Primer mide kanseri hastaları çalışmaya alındı. Nadir tümörleri olan hastalar çalışma dışı bırakıldı. Hastalar 4 gruba ayrıldı; Grup 1: Cerrahiye uygun ve cerrahi rezeksiyon yapılan hastalar, Grup 2: Operasyon sırasında rezeke edilemeyen tespit edilen hastalar, Grup 3: Radyolojik olarak çalışmayan hastalar, Grup 4: Cerrahiyi reddeden hastalar. Gruplar arasında sağkalımı analiz ettik ve etkili faktörleri değerlendirdik.
Bulgular: Çalışmaya 102 hasta alındı. Altmış altı hastaya cerrahi rezeksiyon yapıldı (grup 1). Beş hastaya ameliyat sırasında çalışamazlık tanısı kondu (grup 2). Altı genç hasta radyolojik değerlendirme ile inoperabl olarak belirlendi (grup 3). On beş hasta (grup 4) uygun olarak değerlendirildi; ancak ameliyatı reddetti. Cinsiyete göre gruplar arasında fark bulunmadı (P=0,250)  (Tablo 1). Bununla birlikte, yaş dağılımı, P=0.043 olan gruplar arasında farklıydı çünkü grup 4, yaş ortalaması 71.0 (10,0) olan yaşlı hastalar tarafından oluşturulmuştur. Sağkalım analizi, grup 1'deki hastaların (14.0 (5,1) ay) diğer gruplardan daha iyi sağkalım gösterdiğini gösterdi (P=0,011). Erkek hastalar kadınlara göre daha iyi sağkalım gösterdi (14 (1,9) vs 6 (1,8) ay, P=0,002).
Sonuç: Her ne kadar mide kanseri seyri farklı olsa da, belirli evrelerde uygun cerrahi işlem, kabul edilebilir sağkalım oranları ile uygulanabilir bir tedavi seçeneği gibi görünmektedir.

Anahtar Kelimeler

Mide kanseri, Sağkalım, Hastalığın seyri

Kaynakça

• 1. Al-Refaic WB, Abdalla EK, Ahmed SA, Mansfield PF. Gastric cancer. In: Feig BW, Berger DH,Fuhrman GM, editors. M.D. Anderson Hand Book of Surgical Oncology. Philadelphia: LippincottWilliams & Wilkins; 2006 p.205-240.
• 2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2005;54:209-41.
• 3. Faraji EI, Frank BB. Multifocal atrophic gastritis and gastric carcinoma. Gastroenterol Clin North. Am Gastroenterology. 2002;31:499-516.
• 4. Suehiro T, Hirashita T, Araki S, Matsumata T, Tsutsumi S, Mochiki E, et al. Prolonged antibiotic prophylaxis longer than 24 hours does not decrease surgical site infection afterelective gastric and colorectal surgery. Hepatogastroenterology. 2008;55:1636-9.
• 5. Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Tumor size: a non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol. 2008;97:236-40.
• 6. Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, et al. Prognostic Significance of level and number lymph node metastasis in patiens with gastric cancer. Ann Surg Oncol. 2007;14:1688-93.
• 7. Vasilescu C, Herlea V, Tidor S, Ivanov B, Stănciulea O, Mănuc M, et al. D2 lymph node dissection in gastric cancer surgery: long term results--analysis of an experience with 227 patients. Chirurgia (Bucur). 2006;101:375-84.
• 8. Wu MH, Lin MT, Chen WJ. Effect of perioperative parenteral nutritional support for gastric cancer patients undergoing gastrectomy. Hepatogastroenterology. 2008;55:799-802.
• 9. Huang CM, Lin BJ, Lu HS, Zhang XF, Li P, Xie JW. Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus. World J Gastroenterol. 2008;14:4383-8.
• 10. Know Sj, Kim GS. Prognostic Significance of Lymph Node Metastasis in Advanced Carcinoma of the Stomach. Br J Surg. 1996; 83:1600-3.
• 11. Bozetti F, Marubini E, Bonfanti G. Subtotal versus total gastrectomy for gastric cancer: Five year survival rates in a multicenter randomized Italian trial. Ann Surg. 1999;230:170-8.
• 12. Stewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer. Ten-year results of the German gastric cancer Study. Ann Surg. 1998;228:449-61.
• 13. Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80:412–7.
• 14. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–60.
• 15. Mita MT, Marchesi F, Cecchini S, Tartamella F, Ricco' M, Abongwa HK, et al. Prognostic assessment of gastric cancer: retrospective analysis of two decades. Acta Biomed. 2016; 87:205-11.
• 16. Çelen S, Günseren KÖ, Özlülerden Y, Mete A, Tuncay ÖL, Yavaşcaoğlu İ. Does neutrophil-lymphocyte ratio show recurrence in patients who underwent curative resection for non-muscle-invasive bladder cancer? J Surg Med. 2019;3(4):324-7.
• 17. Tekeşin K, Şişik A. Incidental gallbladder cancer: Review of 3856 cholecystectomies. J Surg Med. 2018;2(2):127-9.
• 18. Kalcan S, Sisik A, Basak F, Hasbahceci M, Kilic A, Kosmaz K, et al. Evaluating factors affecting survival in colon and rectum cancer: A prospective cohort study with 161 patients. J Cancer Res Ther. 2018 Jan-Mar;14(2):416-20. doi: 10.4103/0973-1482.199390.
• 19. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007;96:14-8.